Extended Data Fig. 2: ctDNA is Elevated in MRD-Positive Patients.
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Average ctDNA concentration, in mean tumor molecules/mL of plasma (MTM/mL), across stages (stage I (red, stage II (blue), stage III (green), and stage IV (grey) at the following time points was assessed at: A. Prior to surgery, B. 4 weeks post-surgery (MRD timepoint), C. Patients who cleared their ctDNA at the MRD time point were observed to have lower presurgical ctDNA levels. D. Patients were further stratified by ACT induced ctDNA clearance beyond the 4-weeks post-surgical MRD time point across stages. Patients who cleared ctDNA during ACT had lower ctDNA at the MRD time point. Box plots were generated using ggplot2 package v3.3.6 in R v4.2.1. Center line, median MTM/ml; bottom of box, 25% quantile; top of box, 75% quantile; data points represent outliers. P-values were calculated using the two-sided t-test.
